Results
|
1.
|
Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. MedStar authors:
Year: 2015
Citation: - Journal of Clinical Oncology. 33(12):1340-7, 2015 Apr 20.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - Blackmon NL, Costantino JP, Fehrenbacher L, Finnigan M, Gavin PG, Geyer CE Jr, Jeong JH, Kim SR, Mamounas EP, Paik S, Pogue-Geile KL, Rastogi P, Song N, Swain SM, Wickerham DL, Wolmark N
|
|
2.
|
Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. MedStar authors:
- Alsaadi, Dana
- Charabaty, Aline
- Jennings, Joseph
Year: 2018
Citation: - Journal for Immunotherapy of Cancer. 6(1):142, 2018 Dec 05.
Institution: - MedStar Washington Hospital Center
Department: - Gastroenterology/Hepatology
Medline publication type:
All authors: - Abu-Sbeih H, Ali FS, Alsaadi D, Charabaty A, Gong Z, Jennings J, Luo W, Richards DM, Wang Y
|
|
3.
|
Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer. MedStar authors:
- Mirkheshti, Nooshin
- Qazi, Fahad
Year: 2020
Citation: - European Urology. 77(1):14-21, 2020 01.
Institution: - MedStar Union Memorial Hospital
Medline publication type:
All authors: - Antonarakis ES, Carducci MA, Denmeade SR, Eisenberger MA, Fu W, Isaacsson Velho P, Lima FAS, Markowski MC, Marshall CH, Mirkheshti N, Paller CJ, Qazi F, Shaukat F, Wang H
|
|
4.
|
|